Highest-materiality recent filing
Wave Life Sciences completes redomiciliation to Delaware; shares trade under WVE on Nasdaq
On Aug 7, 2026, Wave Life Sciences, Inc. (Delaware) became parent of Wave Life Sciences Ltd. (Singapore) via scheme of arrangement; shares exchanged 1:1.
Wave Life Sciences Q2 net loss $69.4M; WVE-007 Phase 2a dosing underway; FDA meeting for WVE-006
Net loss $69.4M vs $50.5M YoY; revenue $2.3M vs $8.7M; cash $490.6M, runway into 3Q 2028.
Wave Life Sciences shareholders approve redomiciliation; 155M shares voted in favor
Scheme Shareholders voted 155,190,836 for (99.9%) and 78,429 against; all 87 shareholders voted in favor.
WVE-006 achieved 64.4% wild-type M-AAT (matching protective MZ phenotype) and 70.5% reduction in toxic Z-AAT in 200 mg biweekly cohort.
Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026
Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).
Wave Life Sciences sets Singapore High Court hearing for redomiciliation on Apr 29
Application to convene shareholder meeting for scheme of arrangement filed Apr 16, 2026; hearing on Apr 29 at 10:00 am SGT.
Wave Life Sciences announces redomiciliation to Delaware, shares to exchange 1:1
Parent company to change from Singapore to Delaware corporation via scheme of arrangement.
Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial
Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.
Wave Life Sciences Q4 net loss $53.2M; cash $602.1M; WVE-007 obesity data update expected Q1 2026
Net loss $53.2M in Q4 vs income $29.3M YoY; full year loss $204.4M vs $97.0M.
Wave regains full rights to WVE-006; plans FDA accelerated approval engagement mid-2026
Regained full rights to WVE-006 (RNA editing for AATD) from GSK; no upfront payment mentioned.
Wave Life Sciences reports preliminary $602M cash; outlines 2026 pipeline milestones
Preliminary unaudited cash $602M as of Dec 31, 2025; runway into 3Q 2028.
Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028
Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.
Single 240 mg WVE-007 dose: 9.4% visceral fat loss (p=0.02), 4.5% total fat reduction, 3.2% lean mass gain at 3 months.
Wave Life Sciences updates corporate presentation; no material new data disclosed.
Filed corporate presentation dated November 17, 2025, available on company website.
Wave Life Sciences Q3 net loss $53.9M; obesity drug WVE-007 shows 85% Activin E reduction
WVE-007: dose-dependent Activin E reduction up to 85% in INLIGHT; sustained through 6 months at lowest dose; supports once/twice yearly dosing.
WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.
WVE-007 achieved Activin E reductions of 85% (400mg), 75% (240mg), 56% (75mg) at one month, all highly significant (p<0.0001).
Wave Life Sciences releases updated corporate presentation on September 24, 2025
Presentation posted on company website and furnished as Exhibit 99.1.
Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study
200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels
Wave Life Sciences shareholders approve 8M share increase to equity plan
Shareholders approved 8M share increase to 2021 Equity Incentive Plan (105.9M for, 24.6M against).
Wave Life Sciences updates corporate presentation on August 5, 2025
Company furnished an updated corporate presentation as Exhibit 99.1 to the 8-K.
Wave Life Sciences Q2 2025 net loss $50.5M; cash $208.5M; key trial data on track
Cash $208.5M as of June 30, 2025, down from $302.1M at Dec 31, 2024; runway into 2027.
Wave Life Sciences Q1 2025 net loss $46.9M; pipeline progress in obesity, AATD, DMD, HD
Net loss of $46.9M vs $31.6M prior year; revenue $9.2M (down from $12.5M). Cash $243.1M, runway into 2027.
Wave reports positive Phase 2 FORWARD-53 data for WVE-N531 in DMD; plans NDA in 2026
TTR improved 3.8 seconds vs natural history (p<0.05); fibrosis reduced 28.6% (p<0.01); CK declined 50%.
Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025
Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.
Wave Life Sciences updates corporate presentation, no material details disclosed
Company furnished an updated corporate presentation on January 13, 2025.
Wave Life Sciences updates corporate presentation; no specific new data disclosed
Company filed an updated corporate presentation dated November 20, 2024.
Wave Life Sciences Q3 net loss $61.8M; first RNA editing in humans for AATD achieved
Net loss $61.8M vs net income $7.3M in Q3 2023; revenue ($7.7M) vs $49.2M (including one-time events).
Wave Life Sciences reveals WVE-007 obesity trial startup in Q1 2025, new RNA editing programs
WVE-007 (INHBE GalNAc-siRNA) on track for Phase 1 in Q1 2025; preclinical data show monotherapy, add-on to GLP-1s, and maintenance potential.
Wave achieves first-ever therapeutic RNA editing in humans in RestorAATion-2 trial of WVE-006
Single 200 mg dose in first two Pi*ZZ patients produced mean total AAT ~11 µM at day 15, with edited M-AAT >60% of total.
Takeda terminates HTT option; Wave Life Sciences regains full rights to WVE-003 Huntington's program
Takeda notified Wave it will not exercise option for HTT target, ending collaboration; Takeda previously paid ~$260M to Wave.
Wave Life Sciences posts updated corporate presentation to IR website
Corporate presentation dated October 1, 2024, posted on investor relations page.
Wave Life Sciences prices upsized $200M public offering of ordinary shares and pre-funded warrants
Offering of 23.1M ordinary shares at $8.00/share and 1.9M pre-funded warrants at $7.9999 each; gross proceeds ~$200M.
Mean muscle content-adjusted dystrophin expression 9.0% (range 4.6-13.9%); unadjusted 5.5% (range 3.3-8.3%) in ambulatory boys.
Shareholders approve increase to equity plan shares by 5M at Wave Life Sciences AGM
Shareholders approved amendment to 2021 Equity Incentive Plan, increasing share authorization by 5,000,000 shares.
Q2 net loss $32.9M vs $21.1M YoY; revenue $19.7M vs $22.1M; cash $154M, sufficient into Q4 2025.
Wave Life Sciences reports 46% mHTT lowering in HD trial; allele-selective silencing demonstrated
SELECT-HD: 30 mg WVE-003 Q8W showed 46% mean mHTT reduction vs placebo at 24 weeks (p=0.0007); 44% at 28 weeks (p=0.0002).
Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track
Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.
Cash and equivalents $200.4M at Dec 31, 2023; additional $34M received in Q1 2024; runway expected into Q4 2025.
Wave Life Sciences furnishes updated corporate presentation; no specific new facts disclosed
Filed an 8-K on January 8, 2024, to update its corporate presentation.
Wave Life Sciences closes public offering of 23M shares, raising $115M gross
Underwriters fully exercised option to purchase 3M additional shares, increasing total to 23M.
Wave Life Sciences updates corporate presentation; no specific material changes disclosed
Company furnished an updated corporate presentation dated December 15, 2023 as Exhibit 99.1.
Underwritten public offering of 20M ordinary shares at $5.00/share, gross proceeds ~$100M; 30-day option for additional 3M shares.
Wave Life Sciences Q3 net income $7.3M; initiates first RNA editing clinical program, WVE-006
Net income of $7.3M vs net loss of $39.0M YoY; revenue increase driven by $48.9M in collaboration milestones.
Wave Life Sciences updates corporate presentation; no specific changes disclosed
Filed updated corporate presentation as Exhibit 99.1 on November 9, 2023.
Wave Life Sciences updates corporate presentation on Oct 2, 2023; no specific details furnished
Company posted an updated corporate presentation on its investor website.
Wave Life Sciences unveils INHBE siRNA for obesity, targets 5 new clinical candidates by 2025
New GalNAc-siRNA program targeting INHBE for metabolic disorders including obesity; expects clinical candidate in 4Q 2024.
Wave Life Sciences updates corporate presentation; no material new info
Company filed an updated corporate presentation under Regulation FD on September 5, 2023.
Wave Life Sciences shareholders approve 6.5M share increase to equity plan and 2M to ESPP
Shareholders approved amendment to 2021 Equity Incentive Plan adding 6,500,000 authorized shares.
Wave Life Sciences Q2 net loss narrows to $21.1M; revenue jumps to $22.1M on GSK collaboration
Net loss of $21.1M vs $41.3M YoY; revenue of $22.1M from GSK/Takeda collaborations vs $0.4M in Q2 2022.
On September 21, 2022, Michael Panzara, M.D., MPH, Chief Medical Officer, Head of Therapeutics Discovery and Development of Wave Life Sciences Ltd. (the “Company”), resigned effective as of October 14, 2022 to pursue another opportunity.
Effective as of October 14, 2022, Anne-Marie Li-Kwai-Cheung will be promoted to Chief Development Officer and will assume the Development responsibilities currently held by Dr. Panzara.
Max materiality 0.90 · Median 0.70 · Most common event other_material